AnaptysBio, Inc.

NASDAQ:ANAB

Biotechnology

Healthcare
$47.06 -1.88%

-$1.07 today

Market cap
$1.40B
Beta
0.41
P/E (TTM)
-59.7
EPS (TTM)
-$0.93
52W Low $11.40High $72.36

Volume 0.57M

Average 0.76M

ANAB Net Income

Bottom-line profit, the starting point for calculating cash from operations.

AnaptysBio, Inc.NASDAQ: ANAB

Net Income · Q1 FY2026 · quarter ended Mar 2026

Net income growth accelerates

Q1 FY2026 net income of $52.88M (cash outflow) rose 34.5% year over year, ahead of the -81.0% change in trailing-twelve-month net income.

Context

  • Net income amounted to 21.1% of revenue in FY2025, down 138.0 pp from a year earlier.
  • Net income increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net income reaches the consensus estimate from 1 analysts of $132.02M (+166.1%) for the fiscal year ending Dec 2026, a step up from the +134.2% reported in FY2025.

Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$52.88M-206.6% QoQ
Last fiscal yearDec 2025
$49.61M+134.2% YoY
LTMMar 2026
-$26.79M-81.0% YoY
Net Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+34.5%-18.9%-53.4 pp
1 year+134.2%+166.1%+31.9 pp
3-year CAGR—+63.9%—
5-year CAGR+39.0%—
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Net Income history

USD · from the cash flow

Latest · FY2025
49.61M USD
Year-over-year change
+134.2%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Net Income vs competitors

How ANAB compares with its peers on the latest reported figures

  • ANAB's LTM Mar 2026 net income of $26.79M is the smallest of the 10 companies compared; the peer median is $87.07M.
  • Its year-over-year change of -81.0% is the lowest of 10, against a peer median of +21.4%.
  • Net income amounts to 11.5% of revenue for ANAB, versus a peer median of 4003.0%.
ANAB Competitors Peer median
Net Income for ANAB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMVTImmunovant, Inc.LTM Sep 2026$508.96M +9.5%+33.8%7173.5%
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$259.47M +76.5%+66.1%—
ANNXAnnexon, Inc.LTM Mar 2026$196.48M +17.4%+13.3%—
DNTHDianthus Therapeutics, Inc.LTM Jun 2026$192.25M +67.5%+78.6%10097.0%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$87.07M +21.4%+12.6%—
XNCRXencor, Inc.LTM Jun 2026$71.19M -60.8%+18.5%67.8%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026$69.66M -46.5%-9.3%832.6%
CNTBConnect Biopharma Holdings LimitedFY2025$55.48M +255.0%-21.8%86687.5%
QTTBQ32 Bio Inc.LTM Mar 2026$33.24M +155.6%—61.9%
ANABAnaptysBio, Inc.LTM Mar 2026$26.79M -81.0%—11.5%
ODTXOdyssey Therapeutics, Inc.—— ———
Peer median (excluding ANAB) $87.07M+21.4%+15.9%4003.0%

Competitors are the stored peer set for ANAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(57.8M)(128.72M)(163.62M)(145.23M)49.61M
Depreciation & Amortization2.09M2.34M2.38M2.4M2.42M
Deferred Income Tax00000
Stock-Based Compensation15.35M27.36M33.21M34.05M36.07M
Change in Working Capital(7.49M)6.84M(324K)(66.33M)(80.73M)
Accounts Receivables(876K)(543K)(5.43M)(33.91M)6.92M
Inventory00000
Accounts Payables(4.74M)9.7M10.94M(33.84M)(87.33M)
Other Working Capital(1.87M)(2.32M)(5.83M)1.43M(313K)
Other Non-Cash Items1.93M18.6M7.56M39.77M12.31M
Operating Cash Flow(45.92M)(73.59M)(120.8M)(135.34M)19.7M
Capital Expenditures(1.37M)(358K)(807K)(358K)(87K)
Acquisitions (Net)0394.49M000
Purchases of Investments(118.66M)(802.5M)(303.92M)(380.38M)(196.41M)
Sales of Investments158.85M408.02M449.48M476.13M424.53M
Other Investing Activities15K(394.49M)000
Investing Cash Flow38.84M(394.85M)144.75M95.4M228.03M
Debt Repayment00(11.73M)34.77M(76.8M)
Common Stock Issued2.55M11.83M2.47M100.84M14.26M
Common Stock Repurchased00(50M)(456K)(68.63M)
Dividends Paid00000
Other Financing Activities249.75M32.19M(43K)(8.1M)(1.45M)
Financing Cash Flow252.3M44.02M(59.3M)127.05M(132.61M)
Effect of Forex Changes00000
Net Change in Cash245.21M(424.42M)(35.34M)87.12M115.12M
Free Cash Flow(47.29M)(73.95M)(121.61M)(135.7M)19.61M

AnaptysBio, Inc.

NASDAQ:ANAB

Intrinsic Alpha fair value

Locked

Current Price

$47.06

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.